BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 16633299)

  • 1. Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial.
    Mitry E; Ducreux M; Ould-Kaci M; Boige V; Seitz JF; Bugat R; Breau JL; Bouché O; Etienne PL; Tigaud JM; Morvan F; Cvitkovic E; Rougier P
    Gastroenterol Clin Biol; 2006 Mar; 30(3):357-63. PubMed ID: 16633299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients.
    Ducreux M; Mitry E; Ould-Kaci M; Boige V; Seitz JF; Bugat R; Breau JL; Bouché O; Etienne PL; Tigaud JM; Morvan F; Cvitkovic E; Rougier P
    Ann Oncol; 2004 Mar; 15(3):467-73. PubMed ID: 14998850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients.
    Droz JP; Muracciole X; Mottet N; Ould Kaci M; Vannetzel JM; Albin N; Culine S; Rodier JM; Misset JL; Mackenzie S; Cvitkovic E; Benoit G
    Ann Oncol; 2003 Aug; 14(8):1291-8. PubMed ID: 12881395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
    Wagner AD; Buechner-Steudel P; Wein A; Schmalenberg H; Lindig U; Moehler M; Behrens R; Kleber G; Kuss O; Fleig WE
    Ann Oncol; 2007 Jan; 18(1):82-87. PubMed ID: 17030546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study.
    Janinis J; Papakostas P; Samelis G; Skarlos D; Papagianopoulos P; Fountzilas G
    Ann Oncol; 2000 Feb; 11(2):163-7. PubMed ID: 10761750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of oxaliplatin in combination with continuous infusion of 5-fluorouracil/leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
    Hwang WS; Chao TY; Lin SF; Chung CY; Chiu CF; Chang YF; Chen PM; Chiou TJ
    Anticancer Drugs; 2008 Mar; 19(3):283-8. PubMed ID: 18510174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study.
    Hegewisch-Becker S; Gruber Y; Corovic A; Pichlmeier U; Atanackovic D; Nierhaus A; Hossfeld DK
    Ann Oncol; 2002 Aug; 13(8):1197-204. PubMed ID: 12181242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer.
    Ghosn M; Farhat F; Kattan J; Younes F; Moukadem W; Nasr F; Chahine G
    Am J Clin Oncol; 2007 Feb; 30(1):15-20. PubMed ID: 17278889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer.
    de Gramont A; Vignoud J; Tournigand C; Louvet C; André T; Varette C; Raymond E; Moreau S; Le Bail N; Krulik M
    Eur J Cancer; 1997 Feb; 33(2):214-9. PubMed ID: 9135491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer.
    Novarino A; Satolli MA; Chiappino I; Giacobino A; Bellone G; Rahimi F; Milanesi E; Bertetto O; Ciuffreda L
    Am J Clin Oncol; 2009 Feb; 32(1):44-8. PubMed ID: 19194124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
    André T; Bensmaine MA; Louvet C; François E; Lucas V; Desseigne F; Beerblock K; Bouché O; Carola E; Merrouche Y; Morvan F; Dupont-André G; de Gramont A
    J Clin Oncol; 1999 Nov; 17(11):3560-8. PubMed ID: 10550155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant intraarterial cisplatin, intravenous 5-flourouracil, and split-course radiation therapy for locally advanced unresectable pancreatic adenocarcinoma: a phase II study of the Puget Sound Oncology Consortium (PSOC-703).
    Thomas CR; Weiden PL; Traverso LW; Thompson T
    Am J Clin Oncol; 1997 Apr; 20(2):161-5. PubMed ID: 9124192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen.
    André T; Louvet C; Raymond E; Tournigand C; de Gramont A
    Ann Oncol; 1998 Nov; 9(11):1251-3. PubMed ID: 9862058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer.
    Cassinello J; Escudero P; Salud A; Marcos F; Pujol E; Pérez-Carrión R; Colmenarejo A; González del Val R; Valero J; Oruezábal MJ; Guillem V; García I; Arcediano A; Marfà X
    Clin Colorectal Cancer; 2003 Aug; 3(2):108-12. PubMed ID: 12952567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer.
    Ryan DP; Clark JW; Kulke MH; Fuchs CS; Earle CC; Enzinger PC; Stuart K; Catarius KJ; Winkelmann J; Mayer RJ
    Cancer Invest; 2003; 21(4):505-11. PubMed ID: 14533439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
    Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
    Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.
    ; Ryan DP; Niedzwiecki D; Hollis D; Mediema BE; Wadler S; Tepper JE; Goldberg RM; Mayer RJ
    J Clin Oncol; 2006 Jun; 24(16):2557-62. PubMed ID: 16636336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-fluorouracil and infusional 5-fluorouracil alone in advanced pancreatic carcinoma patients.
    Alliot C
    Ann Oncol; 2004 Oct; 15(10):1576-7; author reply 1577-8. PubMed ID: 15367423
    [No Abstract]   [Full Text] [Related]  

  • 20. A four-arm, randomized, multicenter phase II trial of oxaliplatin combined with varying schedules of 5-fluorouracil as first-line therapy in previously untreated advanced colorectal cancer.
    Ramanathan RK; Bjarnason GA; Bernard SA; Desimone P; Braich T; Evars JP; Hrushesky WJ; Jolivet J
    Clin Colorectal Cancer; 2008 Mar; 7(2):134-9. PubMed ID: 18501073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.